ASX:RAD Radiopharm Theranostics (RAD) Stock Price, News & Analysis → Will this $2 AI stock double overnight? (From Behind the Markets) (Ad) Free RAD Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Radiopharm Theranostics alerts: Email Address Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> About Radiopharm Theranostics Stock (ASX:RAD)Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.Read More Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> RAD Stock News HeadlinesApril 10, 2024 | msn.comLisata wins FDA orphan drug status for bone cancer candidateApril 9, 2024 | msn.comRadiopharmaceutical emerges as the hottest space in biotech; here’s what it means for Clarity PharmaApril 25, 2024 | Behind the Markets (Ad)Will this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!March 16, 2024 | morningstar.comRadiopharm Theranostics Ltd Ordinary SharesFebruary 25, 2024 | msn.comRadiopharmaceutical market expected to reach ~$14B by 2032February 13, 2024 | uk.finance.yahoo.comRadiopharm Theranostics Limited (RDPTF)February 5, 2024 | au.investing.comRadiopharm Theranostics' novel monoclonal antibody shows promise in cancer treatmentJanuary 26, 2024 | au.investing.comRadiopharm Theranostics completes entitlement offer shortfall for $1.7 millionApril 25, 2024 | Behind the Markets (Ad)Will this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!January 20, 2024 | morningstar.comRadiopharm Theranostics Ltd Ordinary Shares RADDecember 27, 2023 | au.investing.comRadiopharm Theranostics to open second Australian site for lung cancer trialDecember 22, 2023 | au.investing.comRadiopharm Theranostics launching Phase 1 lung cancer trials in JanuaryNovember 20, 2023 | au.investing.comRadiopharm Theranostics' $4.85 million R&D refund will support development of radiopharmaceutical productsOctober 30, 2023 | proactiveinvestors.com.auRadiopharm Theranostics launches $10 million entitlement offer to fund clinical trialsOctober 16, 2023 | proactiveinvestors.com.auRadiopharm Theranostics receives FDA greenlight to start Phase 1 imaging trial of RAD 301October 9, 2023 | finance.yahoo.comRAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung CancerOctober 9, 2023 | proactiveinvestors.com.auRadiopharm Theranostics secures approval for Phase 1 PDL1-nanobody non-small cell lung cancer studySeptember 1, 2023 | finance.yahoo.comRadiopharm Theranostics Full Year 2023 Earnings: AU$0.11 loss per share (vs AU$0.17 loss in FY 2022)August 24, 2023 | finance.yahoo.comRadiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate CancerAugust 24, 2023 | proactiveinvestors.comRadiopharm Theranostics expands TerThera supply agreement for prostate cancer treatment trialJuly 24, 2023 | proactiveinvestors.com.auRadiopharm Theranostics appoints experienced radiopharmaceutical developer as VP Medical and Corporate AffairsJuly 23, 2023 | finance.yahoo.comTheradiag Reports Revenue of €6.7 Million for the First Half of 2023, up 6.8%July 19, 2023 | finance.yahoo.comIs Radiopharm Theranostics (ASX:RAD) In A Good Position To Invest In Growth?June 23, 2023 | marketwatch.comRadiopharmaceuticals Global Market is Projected to Reach $12.6 Billion by 2030: Innovative Radiopharmaceuticals to Boost Cardiac ApplicationsJune 9, 2023 | finance.yahoo.comDiamond Equity Research to Host Global Select Emerging Growth Invitational Virtual Investor Conference on June 13th, 2023June 6, 2023 | proactiveinvestors.com.auRadiopharm Theranostics maintains A$0.70 valuation from Diamond Equity ResearchMay 31, 2023 | proactiveinvestors.com.auRadiopharm welcomes positive guidance from FDA to advance PivalateSee More Headlines Receive RAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Radiopharm Theranostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:RAD CUSIPN/A CIKN/A Webwww.riteaid.com Phone17177612633FaxN/AEmployees2,021Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-107.05% Return on Assets-30.84% Debt Debt-to-Equity RatioN/A Current Ratio0.50 Quick Ratio3.43 Sales & Book Value Annual Sales$6.01 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.06 per share Price / BookN/AMiscellaneous Outstanding Shares445,130,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.96 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Paul Edward-Alexander Hopper A.S.i.A (Age 68)B.A (UNSW), FAICD, Founder & Executive Chairman Comp: $271.45kMr. Riccardo CanevariMD, CEO & DirectorMr. Vittorio Puppo M.D.Chief Operating OfficerProf. David MozleyChief Medical Officer & Scientific Advisory Board ChairDr. Thomas H. Tulip Ph.D. (Age 71)Chief Business Officer Comp: $504.74kMr. Phillip HainsCFO & Company SecretaryDr. Scot L. Harper Ph.D. (Age 67)Senior Vice President of Clinical Operations Mr. Bill ReganSenior Vice President of Regulatory StrategyDr. Rama Abu ShmeisSenior VP of Chemistry, Manufacturing & ControlsMr. Nathan Jong C.A.Company SecretaryMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersRiccardo CanevariSold 2,128,815 sharesTotal: $223,525.58 ($0.11/share)Ian TurnerBought 99,980 shares on 8/3/2023Total: $9,898.02 ($0.10/share) This page (ASX:RAD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Radiopharm Theranostics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
